Team
Team

Lena Quambusch, M.Sc.

Position: PhD-student, scholarship holder of Studienstiftung des deutschen Volkes

Room no.: CP-02-111

Telephone no.: +49 231 755 7054

Member of the group since: 10/2016

University degree: M.Sc. in Chemical Biology, TU Dortmund University

 

Expertise: organic synthesis, 2D-NMR, structure-based drug design

Off-Lab activities (hobbies): running, bouldern, theatre, soccer

Research projects:

The protein kinases Akt1, Akt2, and Akt3 are central regulators within cellular signaling networks and transmit oncogenic signals. Even though all three isoforms are highly conserved and it is known that they are involved in many essential processes including proliferation, survival, and metabolism, the individual roles of the different isoforms in health and disease states have not been evaluated thoroughly. To date, only invasive genotypic knock-out studies are reported, and there is an urgent need for pharmacological perturbation studies to dissect the functional role of the individual Akt isoforms. We want to rationally designed and synthesized covalent-allosteric inhibitors with an ideal selectivity profile towards Akt isoforms and further functionalize those as potent probes to eventually allow for the dissection of the biological functions of Akt1, Akt2, and Akt3.

 

Earlier positions:

  • Exchange Semester, University of Vermont, USA
  • Head chef/cook at Ruf Reisen GmbH, Bielefeld
  • Waitress at servgast GmbH, Dortmund
  • Elected Representative in several committees (Student parliament, Faculty board, Election board etc.)

 

Publications:

  1. Landel, I.; Quambusch, L.; Depta, L.; Rauh, D.. Spotlight on AKT: Current Therapeutic Challenges. ACS Med. Chem. Lett. 2020, 11 (3), 225–227.

    DOI PubMed

  2. a) Quambusch, L.; Landel, I.; Depta, L.; Weisner, J.; Uhlenbrock, N.; Müller, M. P.; Glanemann, F.; Althoff, K.; Siveke, J. T.; Rauh, D.. Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity. Angew. Chem. Int. Ed. Engl. 2019, 58 (52), 18823–18829.

    DOI PubMed

    b) Quambusch, L.; Landel, I.; Depta, L.; Weisner, J.; Uhlenbrock, N.; Müller, M. P.; Glanemann, F.; Althoff, K.; Siveke, J. T.; Rauh, D.. Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity. Angew. Chem. 2019, 131 (52), 18999–19005.

    DOI

  3. Uhlenbrock, N.; Smith, S.; Weisner, J.; Landel, I.; Lindemann, M.; Le, T. A.; Hardick, J.; Gontla, R.; Scheinpflug, R.; Czodrowski, P.; Janning, P.; Depta, L.; Quambusch, L.; Müller, M. P.; Engels, B.; Rauh, D.. Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt. Chem. Sci. 2019, 10 (12), 3573–3585.

    DOI PubMed

  4. Weisner, J.; Landel, I.; Reintjes, C.; Uhlenbrock, N.; Trajkovic-Arsic, M.; Dienstbier, N.; Hardick, J.; Ladigan, S.; Lindemann, M.; Smith, S.; Quambusch, L.; Scheinpflug, R.; Depta, L.; Gontla, R.; Unger, A.; Müller, H.; Baumann, M.; Schultz-Fademrecht, C.; Günther, G.; Maghnouj, A.; Müller, M. P.; Pohl, M.; Teschendorf, C.; Wolters, H.; Viebahn, R.; Tannapfel, A.; Uhl, W.; Hengstler, J. G.; Hahn, S. A.; Siveke, J. T.; Rauh, D.. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer. Cancer Res. 2019, 79 (9), 2367–2378.

    DOI PubMed

  5. a) Tesch, R.; Becker, C.; Müller, M. P.; Beck, M. E.; Quambusch, L.; Getlik, M.; Lategahn, J.; Uhlenbrock, N.; Costa, F. N.; Polêto, M. D.; Pinheiro, P. d. S. M.; Rodrigues, D. A.; Sant'Anna, C. M. R.; Ferreira, F. F.; Verli, H.; Fraga, C. A. M.; Rauh, D.. An Unusual Intramolecular Halogen Bond Guides Conformational Selection. Angew. Chem. Int. Ed. Engl. 2018, 57 (31), 9970–9975.

    DOI PubMed

    b) Tesch, R.; Becker, C.; Müller, M. P.; Beck, M. E.; Quambusch, L.; Getlik, M.; Lategahn, J.; Uhlenbrock, N.; Costa, F. N.; Polêto, M. D.; Pinheiro, P. d. S. M.; Rodrigues, D. A.; Sant'Anna, C. M. R.; Ferreira, F. F.; Verli, H.; Fraga, C. A. M.; Rauh, D.. Eine ungewöhnliche intramolekulare Halogenbindung führt zu konformationeller Selektion. Angew. Chem. 2018, 130 (31), 10120–10126.

    DOI

  6. a) Bührmann, M.; Hardick, J.; Weisner, J.; Quambusch, L.; Rauh, D.. Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants. Angew. Chem. Int. Ed. Engl. 2017, 56 (43), 13232–13236.

    DOI PubMed

    b) Bührmann, M.; Hardick, J.; Weisner, J.; Quambusch, L.; Rauh, D.. Kovalente Liganden zur Adressierung einer lipophilen Bindetasche in der MAPK p38 α. Angew. Chem. 2017, 129 (43), 13415–13419.

    DOI